Skip to Content

Representative Publications

View All PubMed Entries

Koehn TA, Trimble LL, Alderson KL, Erbe AK, McDowell KA, Grzywacz B, Hank JA, Sondel PM. Increasing the clinical efficacy of NK and antibody-mediated cancer immunotherapy: potential predictors of successful clinical outcome based on observations in high-risk neuroblastoma. Front Pharmacol. 2012;3:91. PMID: 22623917.

Nettenstrom L, Alderson K, Raschke EE, Evans MD, Sondel PM, Olek S, Seroogy CM. An optimized multi-parameter flow cytometry protocol for human T regulatory cell analysis on fresh and viably frozen cells, correlation with epigenetic analysis, and comparison of cord and adult blood. J Immunol Methods. 2013 Jan 31;387(1-2):81-8. Epub 2012 Oct 9. PMID: 23058673.

Rakhmilevich AL, Alderson KL, Sondel PM. T-cell-independent antitumor effects of CD40 ligation. Int Rev Immunol. 2012 Aug;31(4):267-78. PMID: 22804571.

Rakhmilevich AL, Baldeshwiler MJ, Van De Voort TJ, Felder MA, Yang RK, Kalogriopoulos NA, Koslov DS, Van Rooijen N, Sondel PM. Tumor-associated myeloid cells can be activated in vitro and in vivo to mediate antitumor effects. Cancer Immunol Immunother. 2012 Oct;61(10):1683-97. PMID: 22392192.

Sondel PM, Gillies SD. Current and potential uses of immunocytokines as cancer immunotherapy. Antibodies. 2012;1:149-171.

Yang RK, Kalogriopoulos NA, Rakhmilevich AL, Ranheim EA, Seo S, Kim K, Alderson KL, Gan J, Reisfeld RA, Gillies SD, Hank JA, Sondel PM. Intratumoral hu14.18-IL-2 (IC) induces local and systemic antitumor effects that involve both activated T and NK cells as well as enhanced IC retention. J Immunol. 2012 Sep 1;189(5):2656-64. PMID: 22844125.

Alderson KL, Sondel PM. Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity. J Biomed Biotechnol. 2011;2011:379123. PMID: 21660134.

Buhtoiarov IN, Neal ZC, Gan J, Buhtoiarova TN, Patankar MS, Gubbels JA, Hank JA, Yamane B, Rakhmilevich AL, Reisfeld RA, Gillies SD, Sondel PM. Differential internalization of hu14.18-IL2 immunocytokine by NK and tumor cell: impact on conjugation, cytotoxicity, and targeting. J Leukoc Biol. 2011 Apr;89(4):625-38. PMID: 21248148.

Buhtoiarov IN, Sondel PM, Wigginton JM, Buhtoiarova TN, Yanke EM, Mahvi DA, Rakhmilevich AL. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology. 2011 Feb;132(2):226-39.

Gubbels JA, Gadbaw B, Buhtoiarov IN, Horibata S, Kapur AK, Patel D, Hank JA, Gillies SD, Sondel PM, Patankar MS, Connor J. Ab-IL2 fusion proteins mediate NK cell immune synapse formation by polarizing CD25 to the target cell-effector cell interface. Cancer Immunol Immunother. 2011 Dec;60(12):1789-800. PMID: 21792658.

Johnson EJ, Buhtoiarov IN, Baldeshwiler MJ, Felder MAR, Rooijen NV, Sondel PM, Rakhmilevich AL. Enhanced T cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice. J Immunother. 2011;34:76-84. PMID: 21150715.

Lange BJ, Yang RK, Gan J, Hank JA, Sievers EL, Alonzo TA, Gerbing RB, Sondel PM. Soluble interleukin-2 receptor α activation in a Children's Oncology Group randomized trial of interleukin-2 therapy for pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2011 Sep;57(3):398-405. PMID: 21681921.

Russ AJ, Wentworth L, Xu K, Rakhmilevich A, Seroogy CM, Sondel PM, Suresh M, Cho CS. Suppression of T-cell expansion by melanoma is exerted on resting cells. Ann Surg Oncol. 2011 Dec;18(13):3848-57. PMID: 21465311.

Soto BL, Hank JA, Darjatmoko SR, Polans AS, Yanke EM, Rakhmilevich AL, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM. Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy. Int Immunopharmacol. 2011 Nov;11(11):1877-86. PMID: 21854876.

Soto BL, Hank JA, Van De Voort TJ, Subramanian L, Polans AS, Rakhmilevich AL, Yang RK, Seo S, Kim K, Reisfeld RA, Gillies SD, Sondel PM. The anti-tumor effect of resveratrol alone or in combination with immunotherapy in a neuroblastoma model. Cancer Immunol Immunother. 2011 May;60(5):731-8. PMID: 21340652.

Villablanca JG, London WB, Naranjo A, McGrady P, Ames MM, Reid JM, McGovern RM, Buhrow SA, Jackson H, Stranzinger E, Kitchen BJ, Sondel PM, Parisi MT, Shulkin B, Yanik GA, Cohn SL, Reynolds CP. Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res. 2011 Nov 1;17(21):6858-66. PMID: 21908574.

Yu AL, Gilman AL, Ozkaynak MF, London WB, Kreissman S, Chen H, Smith M, Anderson B, Villablanca J, Matthay KK, Shimada H, Grupp SA, Seeger R, Reynolds CP, Buxton A, Reisfeld RA, Gillies SD, Cohn SL, Maris JM, Sondel PM. Chimeric anti-GD2 antibody with GM-CSF, IL2 and 13-cis retinoic acid for high-risk neuroblastoma: A Children’s Oncology Group (COG) phase 3 study. N Engl J Med. 2010;335:1324-1334.

Shusterman S, London WB, Gillies SD, Hank JA, Voss SD, Seeger RC, Reynolds CP, Kimball J, Albertini MR, Wagner B, Gan J, Eickhoff J, DeSantes KB, Cohn SL, Hecht T, Gadbaw B, Reisfeld RA, Maris JM, Sondel PM. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20;28(33):4969-75.

Mackall CL, Sondel PM. Tumor Immunology and Pediatric Cancer. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 6th Edition. Philadelphia: Lippincott Raven; 2010, 97-122.

Allen CE, Flores R, Rauch R, Dauser R, Murray JC, Pucetti P, Hsu D, Hetherington M, Goldman S, Sondel P, McClain KL. Neurodegenerative Central Nervous System Langerhans Cell Histiocytosis and Coincident Hydrocephalus: Efficacy of Vincrisitne Cytosine Arabinoside Treatment. Pediatr Blood Cancer, 54:416-423,2010

Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim KM, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KD, London WB, Seeger RC, Maris J, and Sondel PM. The Role for Genotypes of Killer Ig-Like Receptors (KIRs), Their Ligands, and Fcγ Receptors on Responses of Neuroblastoma Patients to Hu14.18-IL2: A Children’s Oncology Group Report. Cancer Research, In Press. E-pub ahead of print, Oct. 10, 2010 ; NIHMSID #242706

Galili U, Albertini MR, Sondel PM, Wigglesworth K, Sullivan M, Whalen G. In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of a-gal Glycolipids. Cancers, 2:773-793, 2010 http://www.mdpi.com/journal/cancers

Yang RK and Sondel PM. Anti-GD2 Strategy in the Treatment of Neuroblastoma. Drugs of the Future, 35(8):665-673, 2010. NIHMSID: NIHMS238520

Gilman, A.L., Ozkaynak, F., Matthay, K., Krailo, M., Yu, A., Gan, J., Sternberg, A., Hank, J., Seeger, R., Reaman, G., Sondel, P. 2009. Phase I Study of ch14.18 with GM-CSF and IL-2 in Children with Neuroblastoma Following Autologous Bone Marrow Transplant or Stem Cell Rescue: A Report from the Children’s Oncology Group. J. Clin. Oncol. 2009;27:85-91.

DeSantes, K.D., Sondel, P.M. 2009. Immunotherapy of Cancer. In: Oncology of Infancy and Childhood. Orkin SH, Fisher DE, Look AT, Lux SE, Ginsburg D and Nathan DG (eds). Elsevier, Philadelphia PA. 2009;209-240.

Buhtoiarov, I.N., Rakhmilevich, A.L., Lanier, L.L., Ranheim, E.A., Sondel, P.M. 2009. Naïve mouse macrophages become activated following recognition of L5178Y lymphoma cells via concurrent ligation of CD40, NKG2D, and CD18 molecules. J. of Immunology 2009;182(4):1940-53.

Hank, J.A., Gan, J., Ryu, H., Ostendorf, A., Stauder, M.C., Sternberg, A., Albertini, M.R., Lo, K.M., Gillies, S.D., Eickhoff, J., Sondel, P.M. 2009. Immunogenicity of the Hu14.18-IL2 Immunocytokine Molecule in Adults with Melanoma and Children with Neuroblastoma. Clinical Cancer Research. 2009;15:5923-30.

Johnson, E.E., Yamane, B.H., Lum, H.D., Buhtoiarov, I.N., Rakhmilevich, A.L., Mahvi, D.M., Gillies, S.D., Sondel, P.M. Radiofrequency Ablation Combined with KS-IL2 Immunocytokine (EMD 273066) Results in an Enhanced Anti-tumor Effect Against Murine Colon Adenocarcinoma. Clinical Cancer Research, 2009;15(15):4875-84.

Yamane, B.H., Hank, J.A., Albertini, M.A., Sondel, P.M. 2009. The development pf antibody-IL2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert opinion in Experimental Drugs. 2009;18:991-1000.

Wu Q, Buhtoiarov IN, Sondel PM, Rakhmilevich AL, Ranheim. Effective Immunotherapy in a mouse model of chronic lymphocytic leukemia by
CD40-activated macrophages. J Immunol. 2009 Jun 1;182(11):6771-8. [PMID: 19454672]. NIHMSID: NIHMS120781.2009.

Capitani CM, Cooper LJN, Egeler RM, Handgretinger R, Locatelli F, Sondel PM, Mackall CL. Highlights of the First International “Immunotherapy in Pediatric Oncology:Progress and Challenges” Meeting. J. Pediatric Oncology, 31(4):227-44. [PMID: 19346873] 2009

Rakhmilevich, A.L., Buhtoiarov, I.N., Malkovsky, M., Sondel, P.M. 2008. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunology and Immunotherapy 2008;57:1151-1160.

Johnson, E.E, Lum, H.D., Rakhmilevich, A.L., Schmidt, B.E., Furlong, M., Buhtoiarov, I.N., Hank, J.A., Raubitschek, A., Colcher, D., Reisfeld, R.A., Gillies, S.D., Sondel, P.M. 2008. Intratumoral Immunocytokine Treatment Results in Enhanced Antitumor Activity. In Press. Cancer Imm and Immunother. 2008;57:1891-1902.

Grupp S, Verneris M, Sondel PM, Cooper LJN. Immunotherapy for Pediatric Cancer. Biology of Blood and Marrow Transplant. 14:33-43, 2008

Meany HJ, Seibel N, Sun J, Finklestein JZ, Sato J, Kelleher J, Sondel P, Reaman G. Phase II Trial of Recombinant Tumor Necrosis Factor-a in Combination with Dactinomycin in Children with Recurrent Wilms Tumor. J. Immunother.31:679-683, 2008. PMID: 18600176

Older Publications

Click one of the links below to view the publications for that year.


Last updated: 03/12/2014
webmaster [at] pediatrics [dot] wisc [dot] edu
Copyright © 2014 The Board of Regents of the University of Wisconsin System